Sustained release of proteins from a modified vaginal ring device

Ryan J Morrow; A David Woolfson; Louise Donnelly; Rhonda M Curran; Gavin P Andrews; Dietmar Katinger; R Karl Malcolm

doi:10.1016/j.ejpb.2010.10.010

Sustained release of proteins from a modified vaginal ring device

Ryan J Morrow, A David Woolfson, Louise Donnelly, Rhonda M Curran, Gavin P Andrews, Dietmar Katinger, R Karl Malcolm

Research output: Contribution to journal › Article › peer-review

51 Citations (Scopus)

Abstract

A new vaginal ring technology, the insert vaginal ring (InVR), is presented. The InVR overcomes the current shortfall of conventional vaginal rings (VRs) that are generally ineffectual for the delivery of hydrophilic and/or macromolecular actives, including peptides, proteins and antibodies, due to their poor permeation characteristics in the hydrophobic polymeric elastomers from which VRs are usually fabricated. Release of the model protein BSA from a variety of insert matrices for the InVR is demonstrated, including modified silicone rods, directly compressed tablets and lyophilised gels, which collectively provided controlled release profiles from several hours to beyond 4 weeks. Furthermore, the InVR was shown to deliver over 1 mg of the monoclonal antibody 2F5 from a single device, offering a potential means of protecting women against the transmission of HIV.

Original language	English
Pages (from-to)	3-10
Journal	European Journal of Pharmaceutics and Biopharmaceutics
Volume	77
DOIs	https://doi.org/10.1016/j.ejpb.2010.10.010
Publication status	Published (in print/issue) - 2011

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.ejpb.2010.10.010

Cite this

@article{ba326f348dee48b29a06495a7fe4e06f,

title = "Sustained release of proteins from a modified vaginal ring device",

abstract = "A new vaginal ring technology, the insert vaginal ring (InVR), is presented. The InVR overcomes the current shortfall of conventional vaginal rings (VRs) that are generally ineffectual for the delivery of hydrophilic and/or macromolecular actives, including peptides, proteins and antibodies, due to their poor permeation characteristics in the hydrophobic polymeric elastomers from which VRs are usually fabricated. Release of the model protein BSA from a variety of insert matrices for the InVR is demonstrated, including modified silicone rods, directly compressed tablets and lyophilised gels, which collectively provided controlled release profiles from several hours to beyond 4 weeks. Furthermore, the InVR was shown to deliver over 1 mg of the monoclonal antibody 2F5 from a single device, offering a potential means of protecting women against the transmission of HIV.",

author = "Morrow, {Ryan J} and Woolfson, {A David} and Louise Donnelly and Curran, {Rhonda M} and Andrews, {Gavin P} and Dietmar Katinger and Malcolm, {R Karl}",

year = "2011",

doi = "10.1016/j.ejpb.2010.10.010",

language = "English",

volume = "77",

pages = "3--10",

journal = "European Journal of Pharmaceutics and Biopharmaceutics",

publisher = "Elsevier",

}

TY - JOUR

T1 - Sustained release of proteins from a modified vaginal ring device

AU - Morrow, Ryan J

AU - Woolfson, A David

AU - Donnelly, Louise

AU - Curran, Rhonda M

AU - Andrews, Gavin P

AU - Katinger, Dietmar

AU - Malcolm, R Karl

PY - 2011

Y1 - 2011

N2 - A new vaginal ring technology, the insert vaginal ring (InVR), is presented. The InVR overcomes the current shortfall of conventional vaginal rings (VRs) that are generally ineffectual for the delivery of hydrophilic and/or macromolecular actives, including peptides, proteins and antibodies, due to their poor permeation characteristics in the hydrophobic polymeric elastomers from which VRs are usually fabricated. Release of the model protein BSA from a variety of insert matrices for the InVR is demonstrated, including modified silicone rods, directly compressed tablets and lyophilised gels, which collectively provided controlled release profiles from several hours to beyond 4 weeks. Furthermore, the InVR was shown to deliver over 1 mg of the monoclonal antibody 2F5 from a single device, offering a potential means of protecting women against the transmission of HIV.

AB - A new vaginal ring technology, the insert vaginal ring (InVR), is presented. The InVR overcomes the current shortfall of conventional vaginal rings (VRs) that are generally ineffectual for the delivery of hydrophilic and/or macromolecular actives, including peptides, proteins and antibodies, due to their poor permeation characteristics in the hydrophobic polymeric elastomers from which VRs are usually fabricated. Release of the model protein BSA from a variety of insert matrices for the InVR is demonstrated, including modified silicone rods, directly compressed tablets and lyophilised gels, which collectively provided controlled release profiles from several hours to beyond 4 weeks. Furthermore, the InVR was shown to deliver over 1 mg of the monoclonal antibody 2F5 from a single device, offering a potential means of protecting women against the transmission of HIV.

U2 - 10.1016/j.ejpb.2010.10.010

DO - 10.1016/j.ejpb.2010.10.010

M3 - Article

VL - 77

SP - 3

EP - 10

JO - European Journal of Pharmaceutics and Biopharmaceutics

JF - European Journal of Pharmaceutics and Biopharmaceutics

ER -

Sustained release of proteins from a modified vaginal ring device

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this